Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18630058 | STING SENSITIZING AGENTS | April 2024 | April 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18345892 | ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATES | June 2023 | July 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18068936 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | December 2022 | May 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18068476 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS | December 2022 | May 2025 | Allow | 29 | 1 | 0 | No | No |
| 17996313 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES BY ADP-RIBOSYL CYCLASES | October 2022 | March 2023 | Allow | 5 | 0 | 0 | No | No |
| 17938193 | DOSAGE REGIME | October 2022 | April 2024 | Abandon | 18 | 2 | 0 | No | No |
| 17946782 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | September 2022 | June 2025 | Allow | 33 | 2 | 0 | No | No |
| 17812735 | ANTICANCER COMBINATION THERAPY | July 2022 | May 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17812498 | PROTEIN-POLYMER DRUG CONJUGATES | July 2022 | March 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17812543 | PROTEIN-POLYMER-DRUG CONJUGATES | July 2022 | November 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17582097 | PREPARATION METHOD OF NK CELLS AND USE THEREOF IN THE TREATMENT OF CANCER | January 2022 | August 2023 | Allow | 18 | 1 | 0 | Yes | No |
| 17471723 | THERAPEUTIC BINDING MOLECULES | September 2021 | June 2023 | Allow | 21 | 1 | 0 | Yes | No |
| 17437428 | APPLICATION OF COMBINATION OF QUINOLINE DERIVATIVE AND IMMUNOMODULATOR IN PREPARATION OF ANTITUMOR DRUGS | September 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17436146 | DRUG DELIVERY FOR COMBINATION OF EPIGENETIC MODULATION AND IMMUNE CHECKPOINT BLOCKADE | September 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17464469 | Methods And Compositions For Modifying Transcription Factor Activity by Targeting The Human Mediator Complex Using Cell Penetrating Memetic Peptides And Methods of Treating Cancer Using The Same | September 2021 | October 2023 | Abandon | 26 | 1 | 0 | No | No |
| 17460560 | ANTIBODIES BINDING PD-L1 AND USES THEREOF | August 2021 | March 2023 | Allow | 18 | 0 | 0 | Yes | No |
| 17369321 | Stabilized Formulations Containing Anti-CTLA-4 Antibodies | July 2021 | January 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17420691 | CONJUGATE COMPRISING LIGAND AND CEACAM5 ANTIBODY FAB FRAGMENT | July 2021 | May 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17418145 | ANTI-OX40 MONOCLONAL ANTIBODY AND APPLICATION THEREOF | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17416148 | FN14 ANTIBODIES AND USES THEREOF | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17415529 | COMBINATION HBV THERAPY | June 2021 | May 2025 | Allow | 47 | 1 | 1 | No | No |
| 17413107 | FLT3 AGONIST ANTIBODIES AND USES THEREOF | June 2021 | April 2025 | Allow | 46 | 2 | 0 | Yes | Yes |
| 17303952 | GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY | June 2021 | March 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17245476 | METHODS OF ADMINISTERING ANTI-TIM-3 ANTIBODIES | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17245474 | ANTI-TIM-3 ANTIBODIES | April 2021 | February 2025 | Abandon | 46 | 1 | 0 | Yes | No |
| 17283988 | PHARMACEUTICAL COMPOSITION CONTAINING TAGGED SITE-ANTIHUMAN ANTIBODY FAB FRAGMENT COMPLEX | April 2021 | April 2024 | Allow | 36 | 2 | 0 | No | No |
| 17277828 | TARGETING MOIETY-DRUG GRAFTED IMMUNE CELL COMPOSITIONS AND METHODS OF USE | March 2021 | September 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17169950 | REGIMENS, COMPOSITIONS AND METHODS WITH CAPSAICIN AND TNF-alpha INHIBITOR | February 2021 | July 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17248767 | ANTIBODIES, COMPOSITIONS, AND IMMUNOHISTOCHEMISTRY METHODS FOR DETECTING C4.4A | February 2021 | March 2023 | Allow | 25 | 0 | 0 | No | No |
| 17155936 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | January 2021 | May 2025 | Allow | 51 | 3 | 0 | Yes | No |
| 17140299 | MODULATING RESPONSES TO CHECKPOINT INHIBITOR THERAPY | January 2021 | March 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17256508 | Anti-SIRP-Beta1 Antibodies and Methods of Use Thereof | December 2020 | March 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17255064 | IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE THEREOF | December 2020 | May 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17254795 | TREATMENT OF CANCER WITH CLEVER-1 INHIBITION IN COMBINATION WITH PD-1/PD-L1 INHIBITOR | December 2020 | May 2024 | Abandon | 40 | 3 | 0 | No | No |
| 17125500 | Antibodies binding to HLA-A2/MAGE-A4 | December 2020 | January 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17116543 | Combination Therapy With LIV1-ADC and PD-1 Antagonist | December 2020 | June 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17111816 | THERAPEUTIC METHODS USING ANTIBODY DRUG CONJUGATES (ADCS) | December 2020 | April 2025 | Abandon | 53 | 2 | 1 | No | No |
| 15734922 | TLR7 PEPTIDE CONJUGATES | December 2020 | September 2024 | Abandon | 46 | 1 | 0 | No | No |
| 16953580 | METHODS FOR ASSESSING EFFICACY OF MALT1 INHIBITORS USING AN NF-KB TRANSLOCATION ASSAY | November 2020 | May 2024 | Abandon | 41 | 2 | 0 | No | No |
| 16953597 | NF-KB REGULATED GENE EXPRESSION ASSAY FOR ASSESSING EFFICACY OF MALT1 INHIBITORS | November 2020 | April 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17054920 | TREATMENT OF CANCER | November 2020 | September 2024 | Allow | 46 | 2 | 0 | Yes | No |
| 17093370 | EPHA3 DIRECTED CAR-T CELLS FOR TREATMENT OF TUMORS | November 2020 | June 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17053753 | METHODS OF TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | November 2020 | November 2024 | Allow | 48 | 3 | 0 | Yes | No |
| 17083556 | ANTI-CD47 BASED TREATMENT OF BLOOD CANCER | October 2020 | October 2024 | Allow | 48 | 5 | 0 | Yes | No |
| 17044952 | T-CELL INDUCING VACCINE COMPOSITION COMBINATION AND USES THEREOF | October 2020 | February 2024 | Abandon | 41 | 1 | 0 | No | No |
| 16966789 | COMBINATION OF CELLULAR IMMUNOTHERAPY | October 2020 | August 2024 | Allow | 49 | 1 | 0 | Yes | No |
| 17042013 | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF | September 2020 | March 2024 | Allow | 42 | 1 | 0 | No | No |
| 17030335 | CBL INHIBITORS AND COMPOSITIONS FOR USE IN ADOPTIVE CELL THERAPY | September 2020 | May 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 16982887 | CANCER VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | September 2020 | January 2025 | Allow | 52 | 2 | 0 | Yes | No |
| 16982095 | Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancer | September 2020 | May 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 16981462 | ANTIGENIC PEPTIDES DERIVING FROM PCSK2 AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES | September 2020 | February 2025 | Abandon | 53 | 2 | 0 | No | No |
| 16980318 | ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | September 2020 | May 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16979251 | Use of Anti-HER2 Antibody-Drug Conjugate in Cancer Treatment | September 2020 | September 2024 | Allow | 48 | 1 | 1 | No | No |
| 16976577 | A METHOD OF MODULATING CELL PROLIFERATION | August 2020 | August 2023 | Allow | 36 | 2 | 0 | No | No |
| 16967509 | IMMUNOMODULATORY NANOFILAMENTS | August 2020 | June 2024 | Allow | 46 | 1 | 0 | Yes | No |
| 16963894 | CANNABINOIDS AND DERIVATIVES FOR PROMOTING IMMUNOGENICITY OF TUMOR AND INFECTED CELLS | July 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16961346 | SUBCUTANEOUS ADMINISTRATION OF ANTI-CD38 ANTIBODIES | July 2020 | March 2025 | Allow | 56 | 4 | 0 | Yes | No |
| 16925802 | ANTHRACYCLINE-BASED ANTIBODY DRUG CONJUGATES HAVING HIGH IN VIVO TOLERABILITY | July 2020 | June 2024 | Allow | 48 | 3 | 0 | No | No |
| 16957075 | ROR1-SPECIFIC ANTIGEN BINDING MOLECULES | June 2020 | February 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 16868388 | COMPOSITIONS AND METHODS TO ENHANCE CUTANEOUS WOUND HEALING | May 2020 | October 2023 | Allow | 42 | 2 | 1 | No | No |
| 16760607 | HEAT-INACTIVATED VACCINIA VIRUS AS A VACCINE IMMUNE ADJUVANT | April 2020 | October 2024 | Abandon | 53 | 4 | 1 | No | No |
| 16758980 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | April 2020 | November 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16650273 | METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE INTERMEDIATE BY ADDITION OF ACID AND USE THEREOF | March 2020 | September 2023 | Allow | 42 | 2 | 1 | No | No |
| 16650337 | ANTI-CKAP4 MONOCLONAL ANTIBODY | March 2020 | September 2023 | Allow | 41 | 2 | 0 | No | No |
| 16637705 | BISPECIFIC ANTIGEN-BINDING MOLECULE | February 2020 | August 2024 | Abandon | 55 | 3 | 1 | No | No |
| 16738115 | COMBINATION CANCER THERAPY | January 2020 | May 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16728045 | ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS | December 2019 | August 2024 | Abandon | 55 | 3 | 1 | Yes | No |
| 16625835 | A NOVEL TUMOR VACCINE AND USES THEREOF | December 2019 | May 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16493605 | SELECTIVE CELL DEATH-INDUCING ENZYME SYSTEM | September 2019 | September 2024 | Allow | 60 | 1 | 1 | Yes | No |
| 16483332 | KRAS PEPTIDE VACCINE COMPOSITIONS AND METHOD OF USE | August 2019 | May 2023 | Allow | 45 | 1 | 1 | Yes | No |
| 16478297 | ANTI-CANCER TREATMENTS WITH AN ANTI-MUC1 ANTIBODY AND AN ERBB INHIBITOR | July 2019 | December 2023 | Abandon | 53 | 5 | 0 | No | No |
| 16444691 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | June 2019 | June 2025 | Allow | 60 | 6 | 0 | Yes | Yes |
| 16408002 | COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES | May 2019 | June 2022 | Allow | 37 | 2 | 1 | Yes | No |
| 16334301 | ANTIBODY-POLYMER-DRUG CONJUGATES | March 2019 | June 2023 | Allow | 51 | 3 | 1 | No | No |
| 16329577 | CHIMERIC PROTEINS FOR TARGETING dsRNA | February 2019 | April 2023 | Allow | 49 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SKOKO III, JOHN JOSEPH.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SKOKO III, JOHN JOSEPH works in Art Unit 1643 and has examined 74 patent applications in our dataset. With an allowance rate of 62.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner SKOKO III, JOHN JOSEPH's allowance rate of 62.2% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SKOKO III, JOHN JOSEPH receive 1.78 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SKOKO III, JOHN JOSEPH is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +59.1% benefit to allowance rate for applications examined by SKOKO III, JOHN JOSEPH. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.7% of applications are subsequently allowed. This success rate is in the 62% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.